Related Experiment Video

Updated: May 29, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Caroline J Breitbach1, James Burke, Derek Jonker

  • 1Jennerex Inc., 450 Sansome Street, 16th floor, San Francisco, California 94111, USA.

Nature
|September 3, 2011
PubMed

Insights

A novel poxvirus, JX-594, was engineered for cancer-selective replication and delivery of therapeutic transgenes. Clinical trials show it effectively targets tumors after intravenous infusion, offering a new platform for cancer therapy.

Area of Science:

  • Oncolytic virotherapy
  • Cancer gene therapy
  • Viral vector development

Background:

  • Current cancer therapies struggle to deliver high concentrations of biological molecules selectively to tumors.
  • Systemic delivery of therapeutic agents like peptides and small interfering RNAs (siRNAs) is limited by off-target effects in normal tissues.
  • Poxviruses, adapted for systemic spread, present a potential platform for targeted cancer treatment.

Purpose of the Study:

  • To engineer a poxvirus (JX-594) for cancer-selective replication and transgene expression following intravenous administration.
  • To evaluate the safety and efficacy of JX-594 in delivering therapeutic molecules to tumor tissues in a clinical trial.
  • To establish a platform technology for multifunctional cancer therapeutics and imaging agents.

Main Methods:

  • Engineering of a poxvirus (JX-594) for replication and transgene expression in cancer cells with activated EGFR/Ras pathway.
  • Intravenous administration of JX-594 in a clinical trial setting.
  • Assessment of JX-594's selective infection, replication, and transgene product expression in tumor versus normal tissues.
  • Dose-response evaluation of JX-594's effects.

Main Results:

  • JX-594 demonstrated selective infection and replication in tumor tissues after intravenous infusion.
  • Transgene products were expressed in a dose-dependent manner within the tumors.
  • Normal tissues remained unaffected clinically, indicating a favorable safety profile.
  • The engineered poxvirus platform successfully delivered therapeutic molecules to metastatic solid tumors.

Conclusions:

  • JX-594 functions as an oncolytic virus that selectively targets and replicates within cancer cells.
  • Intravenous administration of JX-594 enables targeted delivery and expression of therapeutic transgenes in human tumors.
  • This poxvirus platform technology holds promise for developing multifunctional agents for cancer treatment and imaging.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...